Transcatheter arterial infusion chemotherapy prior to radiofrequency thermal ablation for single hepatocellular carcinoma reduces the risk of intrahepatic distant recurrence

International Journal of Oncology

Volumn 41, Issue 3, 2012, Pages 903-909

  Nishikawa, Hiroki ^a   Osaki, Yukio ^a   Kita, Ryuichi ^a   Kimura, Toru ^a   Inuzuka, Tadashi ^a   Takeda, Haruhiko ^a   Nakajima, Jun ^a   Matsuda, Fumihiro ^a   Sakamoto, Azusa ^a   Henmi, Shinichiro ^a   Hatamaru, Keiichi ^a   Saito, Sumio ^a   Nasu, Akihiro ^a  

^a OSAKA RED CROSS HOSPITAL   (Japan)

Author keywords

Epirubicin; Hepatocellular carcinoma; Mitomycin; Radiofrequency thermal ablation; Recurrence; Transcatheter arterial infusion chemotherapy

Indexed keywords

EPIRUBICIN; IODINATED POPPYSEED OIL; MITOMYCIN C;

ABDOMINAL BLEEDING; ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTICLE; ASCITES; BILOMA; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; EMULSION; FEMALE; FEVER; FOLLOW UP; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; INTRAHEPATIC DISTANT RECURRENCE; LIVER CELL CARCINOMA; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVERALL SURVIVAL; PERCUTANEOUS DRAINAGE; PNEUMOTHORAX; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RECURRENCE FREE SURVIVAL; RETROPERITONEAL HEMORRHAGE; SIDE EFFECT; THROMBOCYTE COUNT; TRANSCATHETER ARTERIAL INFUSION CHEMOTHERAPY; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR VOLUME;

AGED; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOTHERAPY, ADJUVANT; EPIRUBICIN; ETHIODIZED OIL; FEMALE; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84865041479     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1512     Document Type: Article

References (31)

1. Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet 362: 1907-1917, 2003. (Pubitemid 37518510)
2. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M and Makuuchi M: HCC Expert Panel of Japan Society of Hepatology. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 29: 339-364, 2011.
3. Lencioni R: Loco-regional treatment of hepatocellular carcinoma. Hepatology 52: 762-773, 2010.
4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. New Eng J Med 359: 378-390, 2008.
5. Guy J, Kelley RK, Roberts J, Kerlan R, Yao F and Terrault N: Multidisciplinary management of hepatocellular carcinoma. Clin Gastroenterol Hepatol 10: 354-362, 2012.
6. Zhou WP, Lai EC, Li AJ, Fu SY, Zhou JP, Pan ZY, Lau WY and Wu MC: A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg 249: 195-202, 2009.
7. Izumi R, Shimizu K, Iyobe T, Ii T, Yagi M, Matsui O, Nonomura A and Miyazaki I: Postoperative adjuvant hepatic arterial infusion of lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. Hepatology 20: 295-301, 1994. (Pubitemid 24233352)
8. Nishiguchi S, Shiomi S, Nakatani S, Takeda T, Fukuda K, Tamori A, Habu D and Tanaka T: Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 357: 196-197, 2001. (Pubitemid 32108094)
9. Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, Koike Y, Yoshida H and Omata M: Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 138: 299-306, 2003. (Pubitemid 36205926)
10. Papatheodoridis GV, Lampertico P, Manolakopoulos S and Lok A: Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 53: 348-356, 2010.
11. Schwartz JD, Schwartz M, Mandeli J and Sung M: Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomized clinical trials. Lancet Oncol 3: 593-603, 2002. (Pubitemid 35174678)
12. Ishikawa T, Higuchi K, Kubota T, Seki K, Honma T, Yoshida T and Kamimura T: Prevention of intrahepatic distant recurrence by transcatheter arterial infusion chemotherapy with platinum agents for stage I/II hepatocelluar carcinoma. Cancer 117: 4018-4025, 2011.
13. Chua TC, Liauw W, Saxena A, Chu F, Glenn D, Chai A and Morris DL: Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma. Liver Int 30: 166-174, 2010.
14. Kanematsu T, Inokuchi K, Sugimachi K, Furuta T, Sonoda T, Tamura S and Hasuo K: Selective effects of lipiodolized antitumor agents. J Surg Oncol 25: 218-226, 1984. (Pubitemid 14132618)
15. Bruix J and Sherman M: Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology 42: 1208-1236, 2005.
16. Yamasaki T, Kurokawa F, Shirahashi H, Kusano N, Hironaka K and Okita K: Percutaneous radiofrequency ablation therapy with combined angiography and computed tomography assistance for patients with hepatocellular carcinoma. Cancer 91: 1342-1348, 2001. (Pubitemid 32267046)
17. [No authors listed] Intra-arterial administration of epirubicin in the treatment of nonresectable hepatocellular carcinoma. Epirubicin Study Group for Hepatocellular Carcinoma. Cancer Chemother Pharmacol 19: 183-189, 1987.
18. Kumari R, Sharma A, Ajay AK and Bhat MK: Mitomycin C induces bystander killing in homogenous and heterogeneous hepatoma. Molecular Cancer 8: 87, 2009.
19. Goldberg SN, Grassi CJ, Cardella JF, Charboneau JW, Dodd GD 3rd, Dupuy DE, Gervais D, Gillams AR, Kane RA, Lee FT Jr, et al: Society of Interventional Radiology Technology Assessment Committee; International Working Group on Image-Guided Tumor Ablation. Image-guided tumor ablation: Standardization of terminology and reporting criteria. Radiology 235: 728-739, 2005.
20. National Cancer Institute (USA): Common terminology criteria for adverse events, version 3.0. http://ctep.cancer.gov/reporting/ctc.html. Published August 9, 2006.
21. Lau WY, Yu SC, Lai EC and Leung TW: Transarterial chemoembolization for hepatocellular carcinoma. J Am Coll Surg 202: 155-168, 2006. (Pubitemid 41831485)
22. Lau WY, Lai EC, Leung TW and Yu SC: Adjuvant intraarterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival. Ann Surg 247: 43-48, 2008.
23. Wu CC, Ho YZ, Ho WL, Wu TC, Liu TJ and P'eng FK: Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. Br J Surg 82: 122-126, 1995.
24. Zhang Z, Liu Q, He J, Yang J, Yang G and Wu M: The effect of preoperative transcatheter hepatic arterial chemoembolization on disease-free survival after hepatectomy for hepatocellular carcinoma. Cancer 89: 2606-2612, 2000. (Pubitemid 32011605)
25. Uyama N, Hatano E, Maetani Y, Isoda H, Shibata T, Taura K, Oe S, Naito M, Yasuchika K, Fujii H, Ikai I and Uemoto S: Efficacy and toxicity of transcatheter arterial chemoembolization with cisplatin suspended in lipiodol for unresectable hepatocellular carcinoma. Gan To Kagaku Ryoho 35: 775-780, 2008 (In Japanese).
26. Asahina Y, Tsuchiya K, Tamaki N, Hirayama I, Tanaka T, Sato M, Yasui Y, Hosokawa T, Ueda K, Kuzuya T, Nakanishi H, et al: Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology 52: 518-527, 2010.
27. Kubo S, Tanaka H, Shuto T, Takemura S, Yamamoto T, Uenishi T, Tanaka S, Ogawa M, Sakabe K, Yamazaki K and Hirohashi K: Correlation between low platelet count and multicentricity of hepatocellular carcinoma in patients with chronic hepatitis C. Hepatol Res 30: 221-225, 2004. (Pubitemid 40012407)
28. Kobayashi M, Ikeda K, Kawamura Y, Yatsuji H, Hosaka T, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Saitoh S, Arase Y and Kumada H: High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma. Cancer 115: 571-580, 2009.
29. Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, Capussotti L, Calise F, Pellicci R, Belli G, et al: HCC Italian Task Force: Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 44: 1543-1554, 2006. (Pubitemid 44970357)
30. Kim YS, Lee WJ, Rhim H, Lim HK, Choi D and Lee JY: The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (>2 and <5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion. AJR Am J Roentgenol 195: 758-765, 2010.
31. Ng IO: Prognostic significance of pathological and biological factors in hepatocellular carcinoma. J Gastroenterol Hepatol 13: 666-670, 1998.